Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021-Reference-Cited by-同舟云学术

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021

Published:2023-01-02 Issue:1 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Fortunato Francesca¹,Prato Rosa¹,Iannelli Giuseppina¹,Ascatigno Leonardo¹,Loconsole Daniela²,Lopalco Pier Luigi³,Martinelli Domenico¹^ORCID

Affiliation:

1. Hygiene Unit, Policlinico Foggia Hospital, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy

2. Hygiene Section, Department of Interdisciplinary Medicine, University of Bari, Bari, Italy

3. Department of Biological and Environmental Sciences and Technology, University of Salento, Lecce, Italy

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2209919

Reference26 articles.

1. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

2. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

3. European Centre for Disease Prevention and Control (ECDC). Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA. 2021 May 6 [accessed 2023 Jan 21]. https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-overview-vaccination-strategies-deployment-plans-6-may-2021.pdf.

4. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

5. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England